VST LongI see this one as an epic play in the making. This is just my personal opinion.
Consult the following
finance.yahoo.com
I just see VST doing a lot of the right things, and getting into hot markets in the gaming/tech sectors.
I am in a position, planning to sell 1/3 at previous ATH and perhaps keep the rest for long term.
From a technical perspective. The volume has not been high but its been going up 11 days in a row. And that is impressive to me because the markets have not been good 11 days in row.
I feel that there are some institutions building up positions in it slowely, resulting in price going up steadily but lower volume.
Typically institutional investors will not enter the position at once or quickly, because they will inadvertently pump up the price too much, resulting in them spending a lot more, and so this low volume, steady gain is something I like seeing.
6F6 trade ideas
VST is slowly priming for a major movment. This idea is inspired by a video made by Zac Heartly on youtube:
www.youtube.com
Business model is to make large invest in small startups and taking an equity and control role to help those companies grow as fast as possible.
If you notice the price movement is getting more snug so to speak with the long term trade. Whereas previously, it rarely challenged the trend, recently, its hovering closer and closer now.
The reason for the large increase in August is that VST has developed a 15 minute test for Covid-19.
VST gives you exposure to a variety of markets, it is well diversified (Healthcare, gaming, digital services, Covid play, etc...)
Reversal signs:
MACD and RSI look promising, oversold with room to flip over and the MACD is showing a possible reversal. (Confirmed)
Bounce of the current level that can be confirmed (waiting)
Break above long term tend (waiting)
Confirmation of break above (waiting)
Breaks above the 6 and 20 day moving averages (waiting)
breaks above longer term moving averages (waiting)
VSQTF Looks Like a Red Hot Growth Pandemic StockVictory Square Technologies Inc. (OTC: VSQTF) may have the answer to getting our world back to normal faster!
We are amid the most unprecedented global health crisis of our modern time. As of September 16th, there are now nearly 30 million coronavirus cases worldwide and nearly 100,000 deaths. First-order effects of the pandemic have created huge demand for necessities like accurate virus testing and second- and third-order effects promise to be equally consequential. This is what could get Victory Square Technologies Inc. (OTC: VSQTF) quickly noticed on Wall Street!
The company's portfolio company Victory Square Health is behind the Safetest Covid-19 Antibody Test, which will be critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection.
The antibody data provided by the Safetest Covid-19 IgM/IgG Elisa test kit covers both immunoglobulins type M (IgM) and G (IgG). When IgM antibodies are present, they can indicate that a patient has an active or recent infection with SARS-CoV-2. When IgG antibodies are present, it indicates past infection and exposure. The FDA, Brazil, and EU have already granted permission to market and sell the test. This is just one company among many in Victory Square Technologies Inc. (OTC: VSQTF) portfolio that could change the world!
Victory Square Health Announces Order of 2 Million (2,000,000) UNITS for its Safetest Covid-19™ Test in Brazil.
The Company received an order of 2 Million (2,000,000) UNITS of its Safetest Covid-19™ test in Brazil. This update does not change any other amounts or information reported in the September 21 Press Release.
Safetest Covid-19™ test enables the user to verify whether one is currently infected, has been infected or has never been infected with Covid-19. The Company this past month has:
• Company received an order of 2 Million (2,000,000) UNITS for its Safetest Covid-19™ test in Brazil.
• VS Health received the CE designation from the EU competent authority of Belgium for Safetest Elisa antibody test for distribution, sale, and usage throughout the 27 countries in the European Union.
• VS Health received Brazilian ANIVSA approval for Safetest ELISA antibody test for distribution, sale, and usage throughout Brazil and export to Mercosur Countries (Argentina, Paraguay, Uruguay and Venezuela).
• VS Health received USDA permission to commence marketing, sales and distribution of Safetest Covid-19™ Antibody Elisa Test under EUA.
• VS Health was the first company to be approved in the Ideiagov program supported by the São Paulo State Government for immediate trials and application in the State.
• VS Health increased monthly production of Covid-19 Rapid Tests by an additional 5,000,000 Test Kits to meet increased demand.
• Safetest Covid-19™ IgG /IgM has demonstrated to the U.S. FDA, Brazilian, and European Union authorities 93.3% sensitivity and 98.7% specificity.
The Company continues to present its product for and receive new approvals from Health Authorities and Governments globally. Victory Square Health’s strategy is to receive ongoing global approvals from Governments followed by the Company’s implementation of immediate supply, manufacturing and distribution channels being set up with new partners in those approved jurisdictions/countries for rapid manufacturing, distribution and sales of its product.
“The school session in Brazil commences in October and full compliance and Covid-19 testing is a top priority and thus demand for our accurate and safe testing product has required our Company to immediately seek additional manufacturing channels for Brazil alone,” said Safetest CEO Felipe Peixoto. Peixoto continued, “Key talks are underway with leading manufacturing partners particularly in North America, Europe, and India to ramp up capacity and increase supply channels to meet the increased demand in those regions and on our Company for our proven product.”
The Company is currently engaging industries including but not limited to retail, hospitality, manufacturing, pharmaceutical, correctional facilities, casinos, sport, policing, first-responder, border services, education, transportation, military, government, and more. These industries and associations are important partners for the Company to align with for ongoing adoption, sales, and distribution channels.
Victory Square Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest capitalized upon its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.) Best Regards
VST.C -- Gearing up for Wave 2 up move on COVID-19 newsVST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of several pending orders with large corporate and government bodies. The company is under NDA at the moment but there will be followup news releases as the orders are fulfilled. Their COVID-19 test has received authorization in a number of major jurisdictions, including most recently Brazil which faces one of the worst COVID-19 outbreaks at the moment.
The company reported record numbers in most recent financials, nearly doubling its net income ($4.7M) from the same 6 month period of last year.
Technically, yesterday marked a decisive reversal after ~50% retrace from recent high and it appears the chart is gearing up for Wave 2 move that should see re-test (and likely break) through resistance around 1.10.
----------------------------------------------------------------
Victory Square Health Increases Monthly Production of Rapid Covid-19 Test Kits to Meet Increased Demand with New Manufacturing Agreement with Gold Analisa Diagnostica Ltda
VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc./Safetest (“VS Health” or the "Company") – portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) – is pleased to announce entering into a manufacturing contract for their IgG and IgM Rapid Test Kits for the detection of Covid-19 for sales and distribution globally.
The latest manufacturing agreement will allow the company to produce an additional 5,000,000 VS Health Covid-19 Rapid Tests monthly for Global distribution.
This additional manufacturing contract will also enable the Company to enter into additional global sales agreements in various industries which have shown interest, including retail, hospitality, pharmaceutical, correctional facilities, casino, border services, education, airport, military, government, and more.
“Based on our outreach and discussions, the demand for our exclusive test from distributors around the world is very high,” said Victory Square Health CEO Felipe Peixoto. “Given that demand, this new capacity-building manufacturing contract is a significant boost to our plan to be a positive solution around the world. To that end, Victory Square Health is committed to providing assistance to as many nations as possible through these distribution channels.”
The new Victory Square Health/Safetest manufacturer is Gold Analisa Diagnostica Ltda., a Government-recognized manufacturer of bio products in Brazil and has operated for over 30 years. Gold Analisa is ISO 9001: 2015 certified by DNV - DET NORSKE VERITAS in the scope of production, marketing and technical-scientific advisory services for products for in vitro diagnostic use. Gold Analisa has Anvisa's Good Manufacturing and Control Practices certificate with hivital, and also participates in the PNCQ - National Quality Control Program, sponsored by SBAC – Sociedade Brasileira de Análises Clínicas. Gold Analisa has a distribution network that aims to be close to customers, covering the entire national territory of Brazil.
“We’re completely energized by this critical new manufacturing contract which will allow Victory Square Health to fulfill the tremendous demand for its exclusive Rapid Test kits on a global scale,” said Shafin Diamond Tejani, CEO of Victory Square Technologies, of which Victory Square Health is a portfolio company. “We are actively working together on other production partnership agreements to further increase our production capacity.”